Shield Therapeutics (LSE:STX) Total Stockholders Equity : £27.10 Mil (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Total Stockholders Equity?

Shield Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2023 was £27.10 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Shield Therapeutics's Book Value per Share for the quarter that ended in Jun. 2023 was £0.04. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Shield Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2023 was 0.21.

Shield Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Shield Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Total Stockholders Equity Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Stockholders Equity

Get a 7-Day Free Trial

40.43

32.15

30.28

40.69

5.43

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Stockholders Equity	Get a 7-Day Free Trial													51.01	40.69	32.57	5.43	27.10

Shield Therapeutics (LSE:STX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Shield Therapeutics's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(27.102	-	0)	/	713.036
	=	0.04

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Shield Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.067	+	5.705)	/	27.102
	=	0.21

Shield Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.